Results 151 to 160 of about 41,710 (302)
Journal of Diabetes Investigation, EarlyView.SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura +3 more
wiley +1 more source
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [PDF]
, 2016 Daisuke Koya, Keizo Kanasaki, Sen Shi
core +1 more source
Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review
Journal of the European Academy of Dermatology and Venereology, EarlyView.This review assessed 52 biomarkers predicting systemic therapy response and adverse events in atopic dermatitis. Most studies focused on dupilumab, and findings were inconsistent. IgE and eosinophils were largely non‐predictive, though elevated eosinophils and LDH sometimes indicated poorer outcomes.
Eva Hilger +11 more
wiley +1 more source
The effect of dipeptidyl peptidase-4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center. [PDF]
Kaohsiung J Med Sci, 2023 Hsu YA, Yang TT, Huang SM, Lan CE.
europepmc +1 more source
Obesity Reviews, EarlyView.ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira +8 more
wiley +1 more source
Терапевтический архив, 2013 AIM: To study the impact of intensified therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor vilagliptin or sulfonylurea (SU) on the control of glycemia, weight, and quantitative body composition in patients with type 2 diabetes mellitus (DM-2) who ...
M V Shestakova +6 more
doaj
Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
Obesity Reviews, EarlyView.ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au +9 more
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2013 David ScottClinical Research Development Associates, Rosedale, NY, USAAbstract: Diabetes is the leading cause of chronic kidney disease, and the prevalence of both diseases is rising worldwide.
Scott D
doaj
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, EarlyView.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source